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Heme is an essential, but toxic cofactor required for virtually all aerobic life. As a 
consequence, cells are challenged to safely traffic heme to hemoproteins that reside in every 
subcellular compartment. However, the mechanisms underlying heme transport and trafficking 
are largely unknown. Moreover, it is unclear how various subcellular compartments 
communicate their requirement for heme to the mitochondria, where 
heme is synthesized. In order to determine how different subcellular compartments sense and 
respond to heme deficiency, I have been developing a heme chelator to induce local heme 
deficiencies. Once this is achieved, we can employ transcriptome and proteome profiling to 
determine pathways that enable various organelles to adapt to heme deficiency. Altogether, we 
seek to better understand how cells appropriate and distribute heme to diverse compartments that 













Heme is a prosthetic group that is present in many proteins in the human body. 
Hemeproteins can play a variety of roles in the cell, such as catalysis of certain metabolic 
reactions, movement of electrons within the cell, and inter/intracellular gas binding and 
movement.​1​ Heme has been traditionally considered as a static cofactor that is buried within 
hemoproteins. However, recent results utilizing a genetically modified fluorescent hemoprotein 
as a heme sensor have shown that there is a pool of labile heme, a heme molecule not tightly 
bound to hemoproteins, that may act in various cellular functions such as signaling.​1​ Although 
heme is a vital component to many cellular functions, free heme is cytotoxic to the cell due to its 
ability to oxidize oxygen to a radical species through Fenton reactions. Therefore, heme must be 
highly regulated within the cell.​2​ Mis-regulation of both labile heme and hemeproteins has been 
linked to pathologies that include cancer and heart disease.​3,4​ Understanding how labile heme 
regulation plays a role in these diseases may lead to new treatments.​1  
 
Currently, it is unknown which organelles “need” labile heme the most. If there was a 
localized cellular deficiency in the cell, which organelle would be first to lose its labile heme 
pool to recover from this deficiency? And just as interesting, which organelle would attempt to 
maintain its free heme pools the longest before donating it to the site of the deficiency. For 
example, the nucleus uses labile heme to activate nuclear transcription factors such as ​hap1​.​5 
Therefore, it could be hypothesized that the nucleus would be the last compartment to transfer 
5 
labile heme to a deficient area. The goal of this project was to develop a tool to test similar 
hypothesis.  
 
To be capable to answer questions of such an unknown phenomenon, I have created a 
local heme deficiency using high affinity hemoprotein cytochrome ​b​562​. Overexpression of this 
protein created a heme sink in any compartment in which the construct is overexpressed. Further 





















Literature Review:  
Heme b plays a role in various intracellular biochemical pathways due its chemical 
structure.​6​ The heme molecule consists of a protoporphyrin IX ring around a positively charged 
iron atom. Because the protoporphyrin IX ring is extremely hydrophobic, free heme can disrupt 
cell membranes and cell signaling. The positively charged iron atom in the center of this 
hydrophobic ring is known to create toxic free radicals within the cell. These free radicals can 
lead damage of cellular DNA and various other organelles. Due to this cytotoxicity, heme must 
be tightly regulated within the cell.​1 ​Because of this, scientists have previously considered heme 
to be kinetically inert and tightly buried within hemeproteins. Recent research has shown that 
there is another pool of “labile” heme that makes up 10% of the total heme pool.​7​ Labile heme is 
available for heme signaling and various heme dependent processes such as hemelyation. This 
pool of labile heme must also be tightly trafficked and controlled in the cell, or else it could lead 
to various pathologies such as cancer.​8  
 
Currently, there is not much that is known about how this pool of labile heme is 
trafficked within eukaryotic cells to better understand this baker’s yeast (Saccharomyces 
Cerevisiae), a model eukaryotic organism, will be used. This field of research is critical because 
many diseases such as cancer and heart disease have been previously linked to heme levels. 
Recent research has been performed to better understand the labile heme pool and its regulation. 
Heme trafficking factors such as heme importers/exporters (FLVCR1a and PUG1), heme 
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proteins (Nitric Oxide Synthase), and heme buffering factors (GAPDH). In addition, various 
small molecules such as nitric oxide and hydrogen peroxide have been shown to impact labile 
heme levels as well.​9  
 
Cytochrome ​b​562​ ​had been previously cloned into a low copy number plasmid and 
expressed in order to sequester labile cytosolic heme. This sequestering has allowed for 
determination of cellular signaling processes that are dependent on the presence of labile heme. 
For example, the use of this cytosolic heme chelator has shown that regulation of nuclear 
transcription factor ​hap1​ could be dependent on more than levels of cellular heme synthesis. 
Sequestering labile heme may also lead into insights on various diseases that labile heme is 
misregulated in such as cancer or alzheimer's.​7  
A valuable tool in determination of these discoveries has been the creation of ratiometric 
heme sensors by Hanna et. al. These ratiometric sensors utilize hemeprotein Cytochrome ​b​562​ ​that 
is fused to both mKATE and eGFP as fluorescent reporters. When heme binds to the 
Cytochrome ​b​562​, eGFP fluorescence is quenched while mKATE fluorescence is constant. This 
tool allows for readouts of labile heme in the cell.5 
The previous study utilized Cytochrome ​b​562​ in a low copy number plasmid. I have 
inserted the Cytochrome ​b​562​ into a high copy number plasmid. The purpose of this is to allow 
for higher numbers of the Cytochrome ​b​562​ to be transcribed. This will allow for greater 
sequestering of cytosolic heme. In addition to this, subcellular localization tags will be added to 
the Cytochrome ​b​562​ construct to allow for localized heme deficits. We can monitor these deficits 
by utilizing ratiometric heme sensors previously mentioned and various other techniques such as 
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microscopy and ​hap1​ activity. Observing this phenomenon will allow for a better of 
understanding of labile heme’s role in the cell and how the cell responds to localized heme 
deficiencies.  
Materials and Methods: 
To generate this tool, a primer set was generated to amplify the Cytochrome b​562​ gene 
from the plasmid pRS 316 and a FLAG tag was introduced at the N-terminus of the Cytochrome 
b​562 ​sequence. The primer was generated to contain an ​Spe​I restriction site at the 5’ end of the 
forward primer, and a ​Sac​I restriction site at the 3’ end of the reverse primer. The sequence of 
the primer has been provided in the SI. A PCR was then ran according to the settings present in 
the SI. The DNA was then purified via DNA miniprep. The purified DNA was stored at 0° 
celsius until later use. The amplified Cytochrome ​b​562 ​was then digested using both ​Spe​I and ​Sac​I. 
The digested product was then ligated into plasmid pRS 426 GPD according to the ligation protocol in the 
SI. A test digest was then ran in order to verify the identity of the plasmid. The protocol and test digest 
results can be found in the SI.  
Another set of primers was ​generated to amplify the Galactose promoter from pRS 316 
GAL. The forward primer was designed to introduce a EcoRI restriction site at the 5’ end of the 
gene. The reverse primer was designed to introduce a BamHI site at the 3’ end of the gene. The 
PCR reaction was then ran to amplify this fragment from the original plasmid. The amplified Gal 
promoter sequence was then digested using ​Eco​RI and ​Bam​HI. A ligation reaction was then 
performed to insert the digested product into the pRS 426GPD+Flag-Cyt ​b​562​ construct. A test 
digest was then ran to ensure the correct construct was generated.  
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Once the plasmid was generated, it was transformed into wild type and ​hem1Δ​ yeast 
cells. Next, an anti-flag western blot was then performed to ensure the galactose titratable system 
was operational. Yeast were grown to 1 OD in in SC-URA-LEU media that either contained 1% 
or 0% galactose. The samples were then lysed, and the lysate was ran on an 10% Acrylamide gel. 
The gel was then transferred to a western blot membrane overnight. The membrane was then 
stained with rabbit anti-FLAG antibody.  
Next, cytosolic labile heme sensors HS1 and HS1M7A were cloned into both the 
wildtype and the ​hem1Δ​ yeast strains. To determine whether, the sensors are being expressed, 
plate reader fluorescence was taken at two settings. The first setting was an excitation 
wavelength of 488 nm and an emission wavelength of 510 nm, this was to confirm the 
fluorescence of eGFP. Another reading was taken at 588 nm excitation and a 635 emission. This 
was done to determine that there was mKATE fluorescence. 
After confirmation that overexpression only occured at 1% galactose concentrations and 
the proper labile heme sensors were present in each strain. Both wildtype and ​hem1Δ​ strains 
either  with or without the Flag-Cyt ​b​562 ​were grown in SCE-LEU-URA media to a OD of 1. The 












Generation of a plasmid that contained the Cytochrome ​b​562​-FLAG construct under 
control of a galactose promoter system was confirmed through the western blot shown in figure 
1. No band in the 0% lane is indicative of lack of FLAG tag in the sample. There is a clear dark 
band in both yeast strains at 1% galactose, indicative of transcription of the FLAG construct. 
 
Figure 1:​ ​Cytochrome b​562 ​ expression under galactose induction. Cyt b​562​ expression was induced with 1% 
galactose in the media. The expression of Cyt b​562​ was monitored via immunoblotting using an anti-FLAG tag 
antibody. The darker the band, the more copies of protein are present. 
 
When the sensor was expressed in wild type yeast, there was a statistically significant 
decrease in labile heme levels after both t-tests and post hoc tests were performed,  this is shown 
in Figure 2. However, in ​hem1Δ​  yeast, there was no statistically significant difference between 
the induced and uninduced samples. An enlarged image of the wildtype sample is shown in 
figure 3. Induced wildtype samples had two times less relative labile heme levels compared to 




Figure 2: ​Wildtype and ​hem1Δ yeast containing Cytochrome ​b​562 Galactose induced vs uninduced. Labile heme               
levels were measured using HS1 sensor in triplicate. Both t-tests and and post hoc tests were performed to                  




Figure 3: ​Wildtype Yeast containing the Cytochrome ​b​562 ​ Galactose induced vs uninduced. Labile heme levels were 







This data shows that the chelation of labile heme through over expression of Cytochrome 
b​562​ in Wildtype yeast was successful. This is proved through the 1% galactose sample 
containing a higher ratio of eGFP/mKATE, indicating lack of labile heme. These results are 
further validated through the usage of both an ANOVA and a t-test. Although there was a 2 fold 
increase in fluorescence in the induced sample, it would be optimal if there was a greater 
chelation of labile heme. This gives further motivation for future studies with the goal of fine 
tuning the utilization of this tool  in wildtype yeast.  
Unlike wildtype cells, ​hem1Δ ​cells did not have any noticeable chelation of heme with 
overexpression of Cytochrome ​b​562​. There are some some possible explanations for this 
phenomena. One said explanation is that the labile heme levels in ​hem1Δ ​are too low for a sensor 
such as HS1. This could lead to differences in labile heme being below the limit of detection for 
this specific sensor. To determine whether this is the case, a sensor with a different affinity for 
labile heme, such as HS1M7A, could be cloned into ​hem1Δ ​already containing the construct. 
Another hypothesis is that the ​hem1Δ ​cells may be unable to support the expression of both a 
labile heme sensor and the Cytochrome ​b​562​ construct at the same time due to the cells being 
unable to reach the metabolic requirements. 
Moving forward, there are multiple potential paths to explore to better both the 
expression and the effectiveness of this construct. One reason that this construct is not as 
effective as expected could be due to the disruption of function, structure, or both, by the FLAG 
tag.  To remedy this,  different polypeptide tags, such as a poly-histidine tag, can be tried. In 
addition, it may be possible for greater expression of the construct if it was cloned into a 
13 
different plasmid utilizing a different expression system, such as a phosphate or copper 
dependent system. Along with previously mentioned tactics, it may be possible to more 
effectively chelate labile heme with Cytochrome ​b​562​.  
After optimization of this tool, there are many potential applications and uses. One of 
these applications is attaching different sub- compartimental localizations tags to Cytochrome 
b​562​ to shuttle the protein into different compartments of the cell such as the nucleus, or 
mitochondria. This will allow for the creation of subcompartment specific deficiencies, which 
may aid to further discoveries in the field of heme trafficking, when coupled with other 
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